Search Results
Your search for ,WHo matches 20701 pages
Showing 13501 - 13550Expert Point of View: Sara Hurvitz, MD; Mothaffar Rimawi, MD; and Carlos L. Arteaga, MD
Sara Hurvitz, MD, Director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, commented that in the United States, a bone mineral density test can help identify candidates for bone-modifying agents. “We look at women who are going on...
Ibandronate Fails to Improve Disease-Free Survival in Early Breast Cancer Patients—but With Favorable Trends
Addition of the oral bisphosphonate ibandronate to endocrine therapy did not significantly improve disease-free survival in patients with early breast cancer, according to the first results from the Dutch TEAM IIb trial presented at the 2016 San Antonio Breast Cancer Symposium.1 The results were...
Breast Cancer Experts Question New Recommendations for 21-Gene Recurrence Score Assay
At the 2016 San Antonio Breast Cancer Symposium, a group of breast cancer experts made a case for using the 21-gene Oncotype DX Breast Recurrence Score Assay in node-positive patients, despite ASCO’s latest recommendations to restrict it to node-negative estrogen receptor–positive patients. The...
Selected Abstracts From the 2016 San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, Director of the Breast Oncology Program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program, to give his picks for the most important research presented at the San Antonio Breast Cancer Symposium....
Pertuzumab, Trastuzumab, Plus Aromatase Inhibitor Beneficial in Metastatic Breast Cancer
In the phase II PERTAIN study of locally advanced or metastatic hormone receptor–positive, HER2-positive breast cancer patients, the addition of pertuzumab (Perjeta) to a regimen of trastuzumab (Herceptin) and an aromatase inhibitor in the first-line setting significantly improved progression-free ...
2017 GI Cancers Symposium: Less Than Half of Recommended Adults Screened for Lynch Syndrome
A team of researchers at Fox Chase Cancer Center found that, despite the recommendation of screening guidelines, less than half of adults younger than 50 years old who have colorectal cancer are being screened for Lynch syndrome, a genetic anomaly that increases the risk of colorectal and several...
2017 GI Cancers Symposium: Nivolumab Demonstrated Efficacy and Improved Survival in Patients With Previously Treated Advanced Gastric Cancer
Results of the ONO-4538-12 trial demonstrated that nivolumab (Opdivo) significantly reduced the risk of death by 37% (hazard ratio [HR] = 0.63; P < .0001) in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current ...
Novel Antibody-Drug Conjugate Targets Triple-Negative Breast Cancer
The antibody-drug conjugate sacituzumab govitecan (IMMU-132) produced high objective response rates, many of them quite durable, in a multicenter study of heavily pretreated patients with metastatic triple-negative breast cancer, presented at the 2016 San Antonio Breast Cancer Symposium.1 Trop-2 is ...
Novel Antibody May Reduce Debilitating Symptoms in Patients With Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Hickish et al found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite outcome of stabilizing/improving lean body mass and debilitating...
What Precisely Is Precision Oncology—and Will It Work?
We know from chaos theory that even if you had a perfect model of the world, you’d need infinite precision in order to predict future events. —Nassim Nicholas Taleb The term “precision oncology” is used to describe diverse strategies in cancer medicine ranging from the use of targeted therapies...
Oncology Drug Approvals in 2016
In 2016, the Office of Hematology and Oncology Products of the U.S. Food and Drug Administration (FDA) approved a number of new molecular entities, indications, and tests. The most notable were drug approvals in disease areas such as non–small cell lung cancer, myeloma, head and neck cancer, and...
Similar Survival With Surgery and Chemoradiotherapy in HPV-Negative Oropharyngeal Squamous Cell Cancer
In an observational study reported in JAMA Oncology, Kelly et al found that overall survival was similar with upfront surgery and definitive chemoradiotherapy among patients with newly diagnosed cT1–2 N1–2b human papillomavirus (HPV)-negative oropharyngeal squamous cell carcinoma....
Expert Point of View: Richard Furman, MD
“These results are interesting, important, and relevant for maintenance post chemotherapy, but if we are not using chemotherapy, they may not be relevant,” said Richard Furman, MD, of Weill Cornell Medical College, New York Presbyterian Hospital, New York. He said that newer drugs such as...
FDA Approves Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma
The U.S. Food and Drug Administration (FDA) today approved ibrutinib (Imbruvica) for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti–CD20-based therapy. Accelerated approval was granted for this indication based on...
Venetoclax Plus Rituximab Studied in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase Ib study reported in The Lancet Oncology, Seymour et al found that the combination of the BCL2 inhibitor venetoclax (Venclexta) and the anti-CD20 monoclonal antibody rituximab (Rituxan) was highly active in patients with relapsed or refractory chronic lymphocytic leukemia...
Validation of the Five-Tiered Gleason Grade Grouping System in Patients With Prostate Cancer
Scientists have been able to validate the recently proposed five-tiered system of Gleason grade grouping using population-based data. The study, led by Grace Lu-Yao, PhD, MPH, Associate Director for Population Science at the Sidney Kimmel Cancer Center at Thomas Jefferson University and Vice...
Tucatinib Shows Clinical Benefit in Phase I Trial in HER2-Positive Breast Cancer
Phase I clinical trial data published by Moulder-Thompson et al in Clinical Cancer Research reported that the investigational anticancer agent tucatinib (formerly ONT-380) showed 'notable activity' in the treatment of HER2-positive breast cancer with . The 50 women treated had disease...
What Influences a Woman’s Decision to Stop Chemopreventive Therapy for Breast Cancer?
In an analysis from the Canadian Cancer Trials Group MAP.3 chemoprevention trial reported in the Journal of Clinical Oncology, Meggetto et al found that worsening of overall menopause-specific quality of life was associated with early discontinuation of study treatment in high-risk postmenopausal...
2017 GI Cancers Symposium: Watch-and-Wait Approach for Rectal Cancer Appears an Option for More Patients
Real-world data from a large observational study suggests that omitting surgery in strictly selected patients with a clinical complete response does not compromise outcomes in rectal cancer. The 3-year survival rate among patients who received “watch-and-wait” care after initial cancer...
2017 GI Cancers Symposium: Physical Activity May Be Linked to Longer Survival in Advanced Colorectal Cancer
A new analysis of the CALGB 80405 (Alliance) trial suggests that people with metastatic colorectal cancer who are more physically active fare better than those who are less active. In a large clinical trial, patients who at the time of starting chemotherapy reported engaging in physical activity...
2017 GI Cancers Symposium: PET Scans Can Inform and Improve Treatment for Patients With Esophageal Cancer
Findings from a federally funded clinical trial—CALGB 80803 (Alliance)—point to a new way to improve the outlook for patients with esophageal cancer: using positron-emission tomography (PET) scans to assess tumor response to initial chemotherapy may allow doctors to tailor further...
Clonal Hematopoiesis of Indeterminate Potential at Time of ASCT May Be Linked to Adverse Outcomes in Lymphoma
In a study reported in the Journal of Clinical Oncology, Gibson et al found that clonal hematopoiesis of indeterminate potential at the time of autologous stem cell transplantation (ASCT) in patients with lymphoma was associated with an increased risk of poorer outcomes. Study Details In the...
Prostate Cancer Treatment Rates Drop, Reflecting Change in Screening Recommendations
As some national guidelines now recommend against routine prostate cancer screening, the overall rate of men receiving treatment for the disease declined 42% between 2007 and 2012, a new study published by Borza et al in Health Affairs found. The decline reflects efforts to decrease overdiagnosis...
FDA Accepts sBLA and Grants Priority Review for Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
On January 9, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for atezolizumab (Tecentriq) in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin...
Potential Biomarker of Recurrent Venous Thromboembolism in Cancer Patients Receiving Anticoagulant Therapy
In a biomarker analysis of the CATCH trial reported in the Journal of Clinical Oncology, Khorana et al found that elevated circulating tissue factor levels were associated with an increased risk of recurrent venous thromboembolism in cancer patients on anticoagulant therapy. CATCH was a randomized ...
No Increased Risk of Skeletal Events in Patients With Bone Metastases Taking Zoledronic Acid
A new study published in JAMA reported that patients with bone metastases due to breast cancer, prostate cancer, or multiple myeloma who used zoledronic acid every 12 weeks compared with every 4 weeks did not have in an increased risk of skeletal events over 2 years. In this study, Andrew L....
Ofatumumab vs Rituximab in Salvage Therapy for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The final results of the international phase III ORCHARD study, reported in the Journal of Clinical Oncology by van Imhoff et al, showed no difference in progression-free survival with the addition of ofatumumab (Arzerra) vs rituximab (Rituxan) to cisplatin, cytarabine, and dexamethasone (O-DHAP vs ...
Effect of Sorafenib in Patients With Advanced Hepatocellular Carcinoma May Depend on Hepatitis Status
In a meta-analysis reported in the Journal of Clinical Oncology, Jackson et al found that overall survival with sorafenib (Nexavar) in advanced hepatocellular carcinoma was significantly improved vs comparator treatments among patients who were both hepatitis B virus (HBV)-negative and hepatitis C...
Does Adding Bortezomib to Lenalidomide/Dexamethasone Improve Outcomes in Patients With Newly Diagnosed Myeloma?
In the phase III SWOG S0777 trial reported in The Lancet, Durie et al found that adding bortezomib (Velcade) to lenalidomide (Revlimid)/dexamethasone improved progression-free and overall survival in patients with newly diagnosed myeloma who were not planned for immediate autologous stem cell...
Patients With Non–Small Cell Lung Cancer May Benefit From Delayed Adjuvant Chemotherapy
A new Yale study suggested that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to 4 months after surgery, according to the researchers. The study was published by Salazar et al in JAMA Oncology. Each year, more people die of lung cancer than of...
Older Patients With Lung Cancer Face Significant Treatment Burden
Depending on the type of treatment older patients with lung cancer receive, they can spend an average of 1 in 3 days interacting with the health-care system in the first 60 days after surgery or radiation therapy, according to a study by Yale researchers. These findings were published by Presley in ...
Survival Benefit Reported With Adjuvant Chemotherapy After Nephroureterectomy for Urothelial Carcinoma
In a National Cancer Database analysis reported in the Journal of Clinical Oncology, Seisen et al found that adjuvant chemotherapy after radical nephroureterectomy was associated with an overall survival benefit in patients with locally advanced or regional lymph node–positive upper tract...
Cancer Death Rate Has Dropped 25% Since 1991 Peak, According to American Cancer Society Report
A steady decline over more than 2 decades has resulted in a 25% drop in the overall cancer death rate in the United States. The drop equates to 2.1 million fewer cancer deaths between 1991 and 2014. The news comes from "Cancer Statistics, 2017," the American Cancer Society’s...
How Common Is Cognitive Impairment After Chemotherapy in Breast Cancer Survivors?
In a prospective longitudinal study reported in the Journal of Clinical Oncology, Janelsins et al found that nearly half of women with breast cancer reported a clinically significant decline in cognitive function from before to after chemotherapy, compared with only 10% of age-matched noncancer...
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update of a 2012 ASCO provisional clinical...
Diagnostic Laparoscopy May Predict Result of Primary Cytoreductive Surgery in Suspected Advanced Ovarian Cancer
In a Dutch trial reported in the Journal of Clinical Oncology, Rutten et al found that initial diagnostic laparoscopy can prevent futile primary cytoreductive surgery in patients with suspected advanced-stage ovarian cancer. Study Details In the trial, 201 women who were qualified for primary...
ACCC 2016 Survey Finds Cancer Drug Costs Remain the Most Critical Challenge to Care
As more cost pressures are placed on the health-care system, and the transition to value-based care gains momentum, the Association of Community Cancer Centers’ (ACCC) 7th annual Trends in Cancer Programs survey revealed critical challenges and emerging trends in U.S. cancer programs. The...
Endometrial Cancer Mutations May Be Detectable in Uterine Lavage Fluid Before Cancer Is Diagnosed
Mutations that have been linked to endometrial cancer can be found in the uterine lavage fluid of pre- and postmenopausal women both with and without detectable cancer, according to a study published by Nair et al in PLOS Medicine. “Today, there are no effective screening methods for...
FDA Grants Priority Review for the sNDA for Regorafenib in the Second-Line Systemic Treatment of Liver Cancer
On January 4, the U.S. Food and Drug Administration (FDA) granted Priority Review status for the supplemental New Drug Application (sNDA) for regorafenib (Stivarga) tablets for the second-line systemic treatment of patients with hepatocellular carcinoma in the United States. “Liver cancer is ...
Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer
In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. The study involved 450 patients diagnosed with colorectal cancer at age < 50...
Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer
In a new study published by Jagsi et al in JAMA Surgery, nearly half of patients with early-stage breast cancer considered having double mastectomy, and one in six received it—including many who were at low risk of developing a second breast cancer. Many patients who chose double...
Comparison of Scales for Assessing Cisplatin-Related Ototoxicity in Children
In a study reported in the Journal of Clinical Oncology, Knight et al of the Children’s Oncology Group found that the Society for Industrial and Organizational Psychology Ototoxicity (SIOP) scale may be more sensitive than other classification systems in detecting ototoxicity in children...
Customer Response to Personal Genomic Testing for Cancer Risk
In a study reported in the Journal of Clinical Oncology, Gray et al found that most people receiving cancer-related data through direct-to-consumer personal genomic testing tended not to change health or screening behaviors when an elevated risk was identified. The study involved baseline and...
Is Adding Onartuzumab to Erlotinib of Benefit in Advanced Non–Small Cell Lung Cancer?
In a phase III METLung trial reported in the Journal of Clinical Oncology, Spigel et al found that adding the MET inhibitor onartuzumab to erlotinib (Tarceva) was of no benefit in patients with MET-positive advanced non–small cell lung cancer (NSCLC) who had progressed after platinum-based...
Use of Genetic Testing to Identify Patients With Breast Cancer at High Risk for Venous Thromboembolism
Venous thromboembolism is a serious—and sometimes fatal—complication of cancer and chemotherapy treatment. Since breast cancer is one of the most common cancers, it accounts for a large number of cancer-related cases of venous thromboembolism. Routine thromboprophylaxis, however, is not recommended ...
Maintenance Olaparib in Platinum-Sensitive Recurrent Serous Ovarian Cancer With BRCA Mutation
Maintenance olaparib (Lynparza) appeared to be associated with an overall survival benefit vs placebo in women with platinum-sensitive serous ovarian cancer and BRCA1 and BRCA2 mutations, according to an updated analysis of a phase II trial reported in The Lancet Oncology by Jonathan A. Ledermann,...
Osimertinib Shows Activity in Pretreated EGFR Thr790Met–Positive Advanced NSCLC
In a phase II trial reported in The Lancet Oncology, Glenwood Goss, MD, of The Ottawa Hospital Cancer Centre, University of Ottawa, and colleagues found that osimertinib produced a high response rate in EGFR tyrosine kinase inhibitor–pretreated EGFR Thr790Met (T790M)–positive advanced non–small...
Colonoscopy Screening in Older Adults
A large population-based observational study by Xabier García-Albéniz, MD, PhD, of the Harvard T.H. Chan School of Public Health, and colleagues evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70 to 74 and 75 to 79 has found...
R. Daniel Beauchamp, MD, Receives 2016 Dr. Rodman E. and Thomas G. Sheen Award
R. Daniel Beauchamp, MD, Chair of the Section of Surgical Sciences and the John Clinton Foshee Distinguished Professor of Surgery at the Vanderbilt-Ingram Cancer Center, has been selected to receive the 2016 Dr. Rodman E. and Thomas G. Sheen Award from the New Jersey American College of Surgeons...
Expect Questions About Screening Mammography for Women Aged 75 Years and Older
A study finding that there is no clear cutoff age to stop breast cancer screening has received national coverage in newspapers and CNN as well as in health and medical publications. “I am glad this is catching fire, because it really needs to be out there,” Cindy S. Lee, MD, the study’s lead...
